<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Vertex Pharmaceuticals - Wikipedia</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"d65a1901-91ce-4c28-9c38-19a8361027f9","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Vertex_Pharmaceuticals","wgTitle":"Vertex Pharmaceuticals","wgCurRevisionId":950745030,"wgRevisionId":950745030,"wgArticleId":1913376,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Vertex_Pharmaceuticals","wgRelevantArticleId":1913376,"wgIsProbablyEditable":!0,"wgRelevantPageIsProbablyEditable":!0,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":
"Vertex_Pharmaceuticals_Inc","wgMediaViewerOnClick":!0,"wgMediaViewerEnabledByDefault":!0,"wgPopupsReferencePreviews":!1,"wgPopupsConflictsWithNavPopupGadget":!1,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFMode":"stable","wgMFAmc":!1,"wgMFAmcOutreachActive":!1,"wgMFAmcOutreachUserEligible":!1,"wgMFLazyLoadImages":!0,"wgMFDisplayWikibaseDescriptions":{"search":!0,"nearby":!0,"watchlist":!0,"tagline":!1},"wgMFIsPageContentModelEditable":!0,"wgWMESchemaEditAttemptStepOversample":!1,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Vertex_Pharmaceuticals","wgWikibaseItemId":"Q2744099","wgCentralAuthMobileDomain":!0,"wgEditSubmitButtonLabelPublish":!0,"wgMinervaPermissions":{"watch":!0,"talk":!1},"wgMinervaFeatures":{"beta":!1,"mobileOptionsLink":!0,"categories":!1,"pageIssues":!0,"talkAtTop":!1,"historyInPageActions":!1,
"overflowSubmenu":!1,"tabsOnSpecials":!1,"personalMenu":!1,"mainMenuExpanded":!1,"simplifiedTalk":!0},"wgMinervaDownloadNamespaces":[0]};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.minerva.base.styles":"ready","skins.minerva.content.styles":"ready","skins.minerva.content.styles.images":"ready","mediawiki.hlist":"ready","mediawiki.ui.icon":"ready","mediawiki.ui.button":"ready","skins.minerva.icons.wikimedia":"ready","skins.minerva.mainMenu.icons":"ready","skins.minerva.mainMenu.styles":"ready","mobile.init.styles":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["mediawiki.action.view.redirect","site","mediawiki.page.startup","skins.minerva.options","skins.minerva.scripts","ext.gadget.switcher","ext.centralauth.centralautologin","ext.popups","mobile.init","ext.relatedArticles.readMore.bootstrap","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming",
"mw.externalguidance.init","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.cite.styles%7Cext.wikimediaBadges%7Cmediawiki.hlist%7Cmediawiki.ui.button%2Cicon%7Cmobile.init.styles%7Cskins.minerva.base.styles%7Cskins.minerva.content.styles%7Cskins.minerva.content.styles.images%7Cskins.minerva.icons.wikimedia%7Cskins.minerva.mainMenu.icons%2Cstyles&amp;only=styles&amp;skin=minerva"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=minerva&amp;target=mobile"></script>
<meta name="generator" content="MediaWiki 1.35.0-wmf.28"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta name="theme-color" content="#eaecf0"/>
<meta property="og:image" content="https://upload.wikimedia.org/wikipedia/en/thumb/d/d9/Vertex_logo.svg/1200px-Vertex_logo.svg.png"/>
<meta name="viewport" content="initial-scale=1.0, user-scalable=yes, minimum-scale=0.25, maximum-scale=5.0, width=device-width"/>
<link rel="manifest" href="/w/api.php?action=webapp-manifest"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Vertex_Pharmaceuticals"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Vertex_Pharmaceuticals rootpage-Vertex_Pharmaceuticals stable issues-group-B skin-minerva action-view">
<div id="mw-mf-viewport">
	<div id="mw-mf-page-center">
		<a class="mw-mf-page-center__mask" href="#"></a>
		<header class="header-container header-chrome">
			<form class="header" action="/w/index.php" method="get">
				<nav class="navigation-drawer toggle-list view-border-box">
					<input type="checkbox" id="main-menu-input" class="toggle-list__checkbox" role="button" aria-labelledby="mw-mf-main-menu-button">
					<label for="main-menu-input" id="mw-mf-main-menu-button"
						class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-menu-base20 mw-ui-icon-flush-left toggle-list__toggle"
						title="Open main menu" data-event-name="ui.mainmenu">Open main menu</label>
					<div id="mw-mf-page-left" class="menu toggle-list__list view-border-box">
	<ul id="p-navigation">
			<li class="">
			    <a href="/wiki/Main_Page" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-home" data-event-name="menu.home"><span>Home</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Special:Random#/random" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-die " data-event-name="menu.random"><span>Random</span></a>
			</li>
			<li class="jsonly">
			    <a href="/wiki/Special:Nearby" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-mapPin nearby" data-event-name="menu.nearby"><span>Nearby</span></a>
			</li>
	</ul>
	<ul id="p-personal">
			<li class="">
			    <a href="/w/index.php?title=Special:UserLogin&amp;returnto=Vertex+Pharmaceuticals" class="menu__item--login mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-logIn " data-event-name="menu.login"><span>Log in</span></a>
			</li>
	</ul>
	<ul id="pt-preferences">
			<li class="jsonly">
			    <a href="/w/index.php?title=Special:MobileOptions&amp;returnto=Vertex+Pharmaceuticals" class="menu__item--settings mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-settings " data-event-name="menu.settings"><span>Settings</span></a>
			</li>
	</ul>
	<ul class="hlist">
			<li class="">
			    <a href="/wiki/Wikipedia:About" class="" data-event-name=""><span>About Wikipedia</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Wikipedia:General_disclaimer" class="" data-event-name=""><span>Disclaimers</span></a>
			</li>
	</ul>
</div>

					<label class="main-menu-mask" for="main-menu-input"></label>
				</nav>
				<div class="branding-box">
					<a href="/wiki/Main_Page">
						<span><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></span>
						
					</a>
				</div>
				<div class="search-box">
					<input class="search mw-ui-background-icon-search skin-minerva-search-trigger" type="search" name="search" id="searchInput"
						autocomplete="off" placeholder="Search Wikipedia" aria-label="Search Wikipedia"
						value="">
				</div>
				<nav class="minerva-user-navigation" aria-label="User navigation">
					<div><button id="searchIcon" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-search-base20 skin-minerva-search-trigger" type="submit">Search</button></div>
					
				</nav>
			</form>
		</header>
		<main id="content" class="mw-body">
			<div class="banner-container">
			<div id="siteNotice"></div>
			</div>
			
			<div class="pre-content heading-holder">
				<div class="page-heading">
					<h1 id="section_0">Vertex Pharmaceuticals</h1>
					<div class="tagline"></div>
				</div>
				<nav class="page-actions-menu">
	<ul id="page-actions" class="page-actions-menu__list">
		<li id="language-selector" class="page-actions-menu__list-item">
				<a id="" href="/wiki/Special:MobileLanguages/Vertex_Pharmaceuticals" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-language-base20 mw-ui-icon-with-label-desktop language-selector"
					data-mw="interface"
					data-event-name="menu.languages" role="button" title="Language">Language</a>
		</li>
		<li id="page-actions-watch" class="page-actions-menu__list-item">
				<a id="ca-watch" href="/w/index.php?title=Special:UserLogin&amp;returnto=Vertex+Pharmaceuticals" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-star-base20 mw-ui-icon-with-label-desktop watch-this-article mw-watchlink menu__item--page-actions-watch"
					data-mw="interface"
					data-event-name="menu.watch" role="button" title="Watch">Watch</a>
		</li>
		<li id="page-actions-edit" class="page-actions-menu__list-item">
				<a id="ca-edit" href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=0" class="edit-page menu__item--page-actions-edit mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 mw-ui-icon-with-label-desktop"
					data-mw="interface"
					data-event-name="menu.edit" role="button" title="Edit the lead section of this page">Edit</a>
		</li>
	</ul>
</nav>
<!-- version 1.0.2 (change every time you update a partial) -->

				
				
				<div class="minerva__subtitle"><span class="mw-redirectedfrom">&#160;&#160;(Redirected from <a href="/w/index.php?title=Vertex_Pharmaceuticals_Inc&amp;redirect=no" class="mw-redirect" title="Vertex Pharmaceuticals Inc">Vertex Pharmaceuticals Inc</a>)</span></div>
			</div>
			
			<div id="bodyContent" class="content"><div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><div class="mw-parser-output"><section class="mf-section-0" id="mf-section-0"><p class="mw-empty-elt">
</p>
<p><b>Vertex Pharmaceuticals, Inc.</b> is an American biopharmaceutical company based in <a href="/wiki/Boston,_Massachusetts" class="mw-redirect" title="Boston, Massachusetts">Boston, Massachusetts</a>. It was one of the first biotech firms to use an explicit strategy of <a href="/wiki/Drug_design" title="Drug design">rational drug design</a> rather than <a href="/wiki/Combinatorial_chemistry" title="Combinatorial chemistry">combinatorial chemistry</a>. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in <a href="/wiki/San_Diego,_California" class="mw-redirect" title="San Diego, California">San Diego, California</a>, and Milton Park, near <a href="/wiki/Oxford,_England" class="mw-redirect" title="Oxford, England">Oxford, England</a>.
</p><table class="infobox vcard" style="width:22em"><caption class="fn org">Vertex Pharmaceuticals, Inc.</caption><tbody><tr><td colspan="2" class="logo" style="text-align:center"><a href="/wiki/File:Vertex_logo.svg" class="image"><img alt="Vertex logo.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/d/d9/Vertex_logo.svg/220px-Vertex_logo.svg.png" decoding="async" width="220" height="117" srcset="//upload.wikimedia.org/wikipedia/en/thumb/d/d9/Vertex_logo.svg/330px-Vertex_logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/d/d9/Vertex_logo.svg/440px-Vertex_logo.svg.png 2x" data-file-width="149" data-file-height="79"></a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/List_of_legal_entity_types_by_country" title="List of legal entity types by country">Type</a></div></th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Public_company" title="Public company">Public</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Ticker_symbol" title="Ticker symbol">Traded as</a></th><td style="line-height: 1.35em;"><div class="plainlist"><ul><li><a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>: <a rel="nofollow" class="external text" href="https://www.nasdaq.com/symbol/vrtx">VRTX</a></li><li><a href="/wiki/NASDAQ-100" title="NASDAQ-100">NASDAQ-100</a> component</li><li><a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500</a> component</li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Industry</th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Pharmaceuticals" class="mw-redirect" title="Pharmaceuticals">Pharmaceuticals</a> &amp; <a href="/wiki/Biotherapy" class="mw-redirect" title="Biotherapy">Biotherapeutics</a>)<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">[1]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founded</th><td style="line-height: 1.35em;">1989</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Headquarters</th><td class="label" style="line-height: 1.35em;"><a href="/wiki/Boston,_Massachusetts" class="mw-redirect" title="Boston, Massachusetts">Boston, Massachusetts</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Key people</div></th><td class="agent" style="line-height: 1.35em;"><div class="plainlist">
<ul><li><a href="/wiki/Reshma_Kewalramani" title="Reshma Kewalramani">Reshma Kewalramani</a>, M.D., President and <a href="/wiki/Chief_executive_officer" title="Chief executive officer">CEO</a></li>
<li>Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer</li>
<li>Michael J. Parini, Executive Vice President and Chief Legal, Administrative and Business Development Officer</li>
<li><a href="/wiki/Jeffrey_Leiden" title="Jeffrey Leiden">Jeffrey Leiden</a>, M.D., PhD, Executive Chairman</li>
<li>David Altshuler, M.D., PhD, Executive Vice President, Global Research and Chief Scientific Officer</li>
<li>Amit K. Sachdev, Executive Vice President and Chief Patient Officer</li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Products</th><td style="line-height: 1.35em;"><a href="/wiki/Pharmaceutical" class="mw-redirect" title="Pharmaceutical">Pharmaceuticals</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Revenue</th><td style="line-height: 1.35em;"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> <a href="/wiki/United_States_dollar" title="United States dollar">US$</a>3.04 billion (2018)</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Website</th><td style="line-height: 1.35em;"><a rel="nofollow" class="external text" href="http://www.vrtx.com/">www.vrtx.com</a></td></tr></tbody></table>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none"><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul><li class="toclevel-1 tocsection-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Medicines"><span class="tocnumber">2</span> <span class="toctext">Medicines</span></a>
<ul><li class="toclevel-2 tocsection-3"><a href="#Ivacaftor,_lumacaftor_and_tezacaftor"><span class="tocnumber">2.1</span> <span class="toctext">Ivacaftor, lumacaftor and tezacaftor</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Triple_combination_treatments"><span class="tocnumber">2.2</span> <span class="toctext">Triple combination treatments</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Genetic_therapies"><span class="tocnumber">2.3</span> <span class="toctext">Genetic therapies</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Historical"><span class="tocnumber">2.4</span> <span class="toctext">Historical</span></a>
<ul><li class="toclevel-3 tocsection-7"><a href="#Telaprevir"><span class="tocnumber">2.4.1</span> <span class="toctext">Telaprevir</span></a></li>
</ul></li>
</ul></li>
<li class="toclevel-1 tocsection-8"><a href="#CEO_compensation"><span class="tocnumber">3</span> <span class="toctext">CEO compensation</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Pricing_in_the_UK"><span class="tocnumber">4</span> <span class="toctext">Pricing in the UK</span></a></li>
<li class="toclevel-1 tocsection-10"><a href="#Venture_philanthropy"><span class="tocnumber">5</span> <span class="toctext">Venture philanthropy</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#See_also"><span class="tocnumber">6</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-12"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#External_links"><span class="tocnumber">8</span> <span class="toctext">External links</span></a></li>
</ul></div>

</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(1)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="History">History</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=1" title="Edit section: History" data-section="1" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-1 collapsible-block" id="mf-section-1">
<p>Vertex was founded in 1989 by <a href="/wiki/Joshua_Boger" title="Joshua Boger">Joshua Boger</a><sup id="cite_ref-Globe_2-0" class="reference"><a href="#cite_note-Globe-2">[2]</a></sup> and Kevin J. Kinsella.<sup id="cite_ref-molecule-book_3-0" class="reference"><a href="#cite_note-molecule-book-3">[3]</a></sup></p><p>The company's beginnings were profiled by <a href="/wiki/Barry_Werth" title="Barry Werth">Barry Werth</a> in the 1994 book, <i><a href="/wiki/The_Billion-Dollar_Molecule" title="The Billion-Dollar Molecule">The Billion-Dollar Molecule</a></i><sup id="cite_ref-molecule-book_3-1" class="reference"><a href="#cite_note-molecule-book-3">[3]</a></sup> and it's further developed in his 2014 book, <i>The Antidote: Inside the World of New Pharma</i>.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4">[4]</a></sup></p><p>By 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and <a href="/wiki/Cancer" title="Cancer">cancer</a>.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">[5]</a></sup></p><p>In 2009, the company had about 1,800 employees, including 1,200 in the Boston area.<sup id="cite_ref-Globe_2-1" class="reference"><a href="#cite_note-Globe-2">[2]</a></sup> By 2019 there were about 2,500 employees.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup></p><p>Since late 2011, Vertex has ranked among the top 15 best performing companies on the <a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">Standard &amp; Poor's 500</a>. Vertex shares increased 250 percent in the same period.<sup id="cite_ref-Boston_Globe_2015_7-0" class="reference"><a href="#cite_note-Boston_Globe_2015-7">[7]</a></sup> In January 2014, Vertex completed its move from <a href="/wiki/Cambridge,_Massachusetts" title="Cambridge, Massachusetts">Cambridge, Massachusetts</a> to <a href="/wiki/Boston,_Massachusetts" class="mw-redirect" title="Boston, Massachusetts">Boston, Massachusetts</a>, and took residence in a new, $800 million complex. Located on the South Boston waterfront, it marked the first time in the company's history that all of the roughly 1,200 Vertex employees in the Greater Boston area worked together.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8">[8]</a></sup></p><p>On 23 January 2019, Ian Smith, the COO and interim CFO of Vertex was terminated from his position for undisclosed personal behavior that violated established company <a href="/wiki/Code_of_conduct" title="Code of conduct">code of conduct</a> rules.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">[9]</a></sup> In June of the same year, Vertex announced it would acquire Exonics Therapeutics for up to $1 billion and collaborate with CRISPR Therapeutics, boosting its development of treatments for <a href="/wiki/Duchenne_muscular_dystrophy" title="Duchenne muscular dystrophy">Duchenne muscular dystrophy</a> and Myotonic Dystrophy Type 1.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">[10]</a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11">[11]</a></sup></p><p>In September 2019 the company announced it would acquire Semma Therapeutics for $950 million in cash.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">[12]</a></sup> Semma Therapeutics created a "small, implantable device that holds millions of replacement beta cells, letting glucose and insulin through but keeping immune cells out."<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">[13]</a></sup></p><p>On 1 April 2020, former Chief Medical Officer, Reshma Kewalramani, became President and Chief Executive Officer of Vertex Pharmaceuticals.<sup id="cite_ref-:1_14-0" class="reference"><a href="#cite_note-:1-14">[14]</a></sup> Former CEO and President Jeffrey Leiden transitioned to the role of Executive Chairman of the Board of Directors, as of 1 April 2020.<sup id="cite_ref-:1_14-1" class="reference"><a href="#cite_note-:1-14">[14]</a></sup> Dr. Leiden will serve as Executive Chairman until April 2023.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">[15]</a></sup><sup id="cite_ref-16" class="reference"><a href="#cite_note-16">[16]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(2)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Medicines">Medicines</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=2" title="Edit section: Medicines" data-section="2" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-2 collapsible-block" id="mf-section-2">
<h3 class="in-block"><span id="Ivacaftor.2C_lumacaftor_and_tezacaftor"></span><span class="mw-headline" id="Ivacaftor,_lumacaftor_and_tezacaftor">Ivacaftor, lumacaftor and tezacaftor</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=3" title="Edit section: Ivacaftor, lumacaftor and tezacaftor" data-section="3" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>In 2012 <a href="/wiki/Ivacaftor" title="Ivacaftor">ivacaftor</a>, was designated as an <a href="/wiki/Orphan_drug" title="Orphan drug">orphan drug</a>, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States. On 31 January 2012, Vertex gained FDA approval<sup id="cite_ref-FDA_2011_17-0" class="reference"><a href="#cite_note-FDA_2011-17">[17]</a></sup> of the first drug, Kalydeco,<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">[18]</a></sup> to treat the underlying cause of <a href="/wiki/Cystic_fibrosis" title="Cystic fibrosis">cystic fibrosis</a> rather than the symptoms, in patients 6 years or older who have the G551D gene <a href="/wiki/Mutation" title="Mutation">mutation</a>. In the US, 30,000 people have cystic fibrosis. 
</p><p>About 4% of those, or 1,200, have the G551D gene mutation. In 2017 Vertex marketed the drug for $311,000 per year.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">[19]</a></sup><sup id="cite_ref-20" class="reference"><a href="#cite_note-20">[20]</a></sup></p><p>Vertex also studied ivacaftor in combination with another drug (<a href="/wiki/Lumacaftor" title="Lumacaftor">lumacaftor</a><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup>) for the most common mutation in cystic fibrosis (CF), known as F508del, and published the first set of results in 2012. Vertex produced the drug after 13 years of research and development, with $70 million in support from the <a href="/wiki/Cystic_Fibrosis_Foundation" title="Cystic Fibrosis Foundation">Cystic Fibrosis Foundation</a>.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup><sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup></p><p>In the UK, the company provided the drug free for a limited time for certain patients. Subsequently, the hospitals decided to continue to pay for the drug for those patients. UK agencies estimated the cost per <a href="/wiki/Quality-adjusted_life_year" title="Quality-adjusted life year">quality adjusted life year</a> (QALY) at between £335,000 and £1,274,000—far above the <a href="/wiki/National_Institute_for_Health_and_Care_Excellence" title="National Institute for Health and Care Excellence">NICE</a> thresholds<sup id="cite_ref-BMJ-2014_24-0" class="reference"><a href="#cite_note-BMJ-2014-24">[24]</a></sup> of £20,000-£30,000.
</p><p>On 5 November 2014 Vertex announced the submission of a <a href="/wiki/New_Drug_Application" title="New Drug Application">New Drug Application</a> (NDA) to the <a href="/wiki/FDA" class="mw-redirect" title="FDA">FDA</a> for a fully co-formulated combination of lumacaftor and ivacaftor for people with <a href="/wiki/Cystic_fibrosis" title="Cystic fibrosis">cystic fibrosis</a> ages 12 and older who have two copies of the <a href="/wiki/Cystic_fibrosis_transmembrane_conductance_regulator#DeltaF508" title="Cystic fibrosis transmembrane conductance regulator">F508del mutation</a> in the <a href="/wiki/Cystic_fibrosis_transmembrane_conductance_regulator" title="Cystic fibrosis transmembrane conductance regulator">cystic fibrosis transmembrane conductance regulator</a> (CFTR) gene.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">[25]</a></sup> In 2015, FDA approved the combination of lumacaftor and ivacaftor to treat CF in patients 12 years and older, who have the F<i>508del</i> mutation. The combination drug is marketed under the tradename <a href="/wiki/Orkambi" class="mw-redirect" title="Orkambi">Orkambi</a>.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">[26]</a></sup></p><p>On 28 March 2017, Vertex announced Phase 3 data from a dual combination treatment, tezacaftor plus ivacaftor, in patients with cystic fibrosis.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">[27]</a></sup> On 12 February 2018, the FDA approved the combination, marketed as Symdeko.<sup id="cite_ref-cystic_28-0" class="reference"><a href="#cite_note-cystic-28">[28]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Triple_combination_treatments">Triple combination treatments</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=4" title="Edit section: Triple combination treatments" data-section="4" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>In 2016, Vertex began developing a new group of CFTR modulators in combination with tezacaftor and ivacaftor.<sup id="cite_ref-cystic_28-1" class="reference"><a href="#cite_note-cystic-28">[28]</a></sup> In 2017, the company reported results that showed benefits for patients with different mutations that represent 90% of the CF population.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">[29]</a></sup>
On 22 October 2019, the FDA approved Vertex's Triple-combo therapy "TRIKAFTA (<a href="/wiki/Elexacaftor/ivacaftor/tezacaftor" title="Elexacaftor/ivacaftor/tezacaftor">elexacaftor/tezacaftor/ivacaftor</a>)" for patients 12 and older with at least one F508del mutation. This approval came only 2 months after the NDA was filed.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">[30]</a></sup> Trikafta is approved for approximately 90% of patients with cystic fibrosis.<sup id="cite_ref-:0_31-0" class="reference"><a href="#cite_note-:0-31">[31]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Genetic_therapies">Genetic therapies</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=5" title="Edit section: Genetic therapies" data-section="5" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>In 2015, Vertex entered into a research collaboration with CRISPR Therapeutics to develop gene-editing therapies for genetic diseases.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">[32]</a></sup> In 2016, the company entered into a collaboration with <a href="/wiki/Moderna_Therapeutics" class="mw-redirect" title="Moderna Therapeutics">Moderna</a> to develop new <a href="/wiki/Messenger_RNA" title="Messenger RNA">mRNA</a>-based therapeutics to treat CF; Vertex paid Moderna $20M in cash and provided an additional $20M in cash in exchange for a <a href="/wiki/Convertible_note" class="mw-redirect" title="Convertible note">convertible note</a> that Vertex can cash in for stock.  Vertex also promised to pay up to $275M in <a href="/wiki/Biodollar" class="mw-redirect" title="Biodollar">milestone payments</a>.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">[33]</a></sup> In 2019, Vertex established a research collaboration with Arbor Biotechnologies to discover novel proteins to advance the development of new gene-edition therapies for cystic fibrosis and four other diseases.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">[34]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Historical">Historical</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=6" title="Edit section: Historical" data-section="6" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<h4 class="in-block"><span class="mw-headline" id="Telaprevir">Telaprevir</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=7" title="Edit section: Telaprevir" data-section="7" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Telaprevir" title="Telaprevir">Telaprevir</a></div>
<p>In 2014, Vertex discontinued telaprevir.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">[35]</a></sup> In May 2011, the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approved the drug telaprevir (Incivek), an oral treatment for <a href="/wiki/Hepatitis_C" title="Hepatitis C">hepatitis C</a> marketed by Vertex. Development and commercialization of telaprevir is shared with <a href="/wiki/Johnson_%26_Johnson" title="Johnson &amp; Johnson">Johnson &amp; Johnson</a> for European distribution and <a href="/wiki/Mitsubishi" title="Mitsubishi">Mitsubishi</a> for Asia. Telaprevir is a <a href="/wiki/Protease_inhibitor_(pharmacology)" title="Protease inhibitor (pharmacology)">protease inhibitor</a>.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(3)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="CEO_compensation">CEO compensation</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=8" title="Edit section: CEO compensation" data-section="8" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-3 collapsible-block" id="mf-section-3">
<p>In 2015, several media outlets reported CEO Jeffrey Leiden's 2014 compensation to be approximately US$48.5 million.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup> Vertex shareholders opted for a reduction in CEO compensation in 2015 and 2016, resulting in 2016 earnings of US$17.4 million.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">[38]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(4)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Pricing_in_the_UK">Pricing in the UK</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=9" title="Edit section: Pricing in the UK" data-section="9" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-4 collapsible-block" id="mf-section-4">
<p>Criticism of Vertex-based around claims that the pricing of their groundbreaking cystic fibrosis drug Orkambi (priced at <a href="/wiki/United_States_dollar" title="United States dollar">US$</a>135,000 to <a href="/wiki/United_States_dollar" title="United States dollar">US$</a>270,000 per patient per year, depending on the patient's country), limited access to the drug for children and young adults with cystic fibrosis, resulted in campaigns by concerned parent groups and allegations of unfair pricing by the UK's <a href="/wiki/National_Health_Service_(England)" title="National Health Service (England)">National Health Service</a>.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">[39]</a></sup><sup id="cite_ref-40" class="reference"><a href="#cite_note-40">[40]</a></sup><sup id="cite_ref-41" class="reference"><a href="#cite_note-41">[41]</a></sup><sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup><sup id="cite_ref-43" class="reference"><a href="#cite_note-43">[43]</a></sup></p><p>In March 2019, Vertex was legally required to destroy 7,880 packs of Orkambi that reached their expiry dates during negotiations with the NHS concerning the drug's pricing.<sup id="cite_ref-Boseley_2019_44-0" class="reference"><a href="#cite_note-Boseley_2019-44">[44]</a></sup><sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup></p><p>On October 24, 2019, Vertex reached an agreement with <a href="/wiki/NHS_England" title="NHS England">NHS England</a> which provided improved access to all of the pharmaceutical company's cystic fibrosis medications that are already licensed, such as Orkambi, Symkevi and Kalydeco, and any future indications of these medicines. The deal was finalized soon after Vertex signed reimbursement deals elsewhere, including <a href="/wiki/NHS_Scotland" title="NHS Scotland">NHS Scotland</a>, Spain and Australia.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46">[46]</a></sup><sup id="cite_ref-:0_31-1" class="reference"><a href="#cite_note-:0-31">[31]</a></sup>  The NHS in Wales and Northern Ireland will be offered equivalent pricing terms.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47">[47]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(5)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Venture_philanthropy">Venture philanthropy</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=10" title="Edit section: Venture philanthropy" data-section="10" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-5 collapsible-block" id="mf-section-5">
<p>In the late 1990s the Bethesda-based <a href="/wiki/Cystic_Fibrosis_Foundation" title="Cystic Fibrosis Foundation">Cystic Fibrosis Foundation</a>, encouraged by then-President Robert Beall, began investing in Vertex— when it was a small start-up biotechnology company— to help fund the development of <a href="/wiki/Ivacaftor" title="Ivacaftor">Kalydeco</a> in the form of <a href="/wiki/Venture_philanthropy" title="Venture philanthropy">venture philanthropy</a>. The total investment amounted to $150 million.<sup id="cite_ref-NYT_2014_48-0" class="reference"><a href="#cite_note-NYT_2014-48">[48]</a></sup> In 2014, the CF Foundation sold the rights to the royalties of the drugs for $3.3 billion, twenty times the foundation's 2013 budget.<sup id="cite_ref-NYT_2014_48-1" class="reference"><a href="#cite_note-NYT_2014-48">[48]</a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49">[49]</a></sup> Proponents of venture philanthropy say the high financial return helps speed drug development and also provides potential monetary rewards that can go to more research.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">[50]</a></sup></p><p>By 2015 the annual price of Kalydeco had been increased to more than $300,000 per patient.<sup id="cite_ref-Dennis_WP_2015_51-0" class="reference"><a href="#cite_note-Dennis_WP_2015-51">[51]</a></sup></p><p>According to an article published in the <i>Milwaukee Journal Sentinel</i> Vertex executives "grossed more than $100 million by cashing in stocks and stock options" and at "one point, the value of company's stock increased more $6 billion in a single day."<sup id="cite_ref-medpage_52-0" class="reference"><a href="#cite_note-medpage-52">[52]</a></sup></p><p>Twenty-nine physicians and scientists working with people with cystic fibrosis (CF) wrote to Jeff Leiden, CEO of Vertex Pharmaceuticals to plead for lower prices.<sup id="cite_ref-Vertex_letter_2012_53-0" class="reference"><a href="#cite_note-Vertex_letter_2012-53">[53]</a></sup></p>
<style data-mw-deduplicate="TemplateStyles:r886047036">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class="templatequote"><p>We are aware of the financial complexities of the huge expenses for R &amp; D with respect to the small number of patients or the market system that enables these advances to become reality. Yet – notwithstanding all your patient support programs – it is at best unseemly for Vertex to charge our patients' insurance plans (including strapped state medical assistance plans), $294,000 annually for two pills a day (a 10-fold increase in a typical patient's total drug costs). This action could appear to be leveraging pain and suffering into huge financial gain for speculators, some of whom were your top executives who reportedly made millions of dollars in a single day (Boston Globe, 29 May).</p><div class="templatequotecite">— <cite>David M. Orenstein, MD et al.</cite></div></blockquote>
<p>The company responded in an email that "while publicly funded academic research provided important early understanding of the cause of cystic fibrosis, it took Vertex scientists 14 years of their own research, funded mostly by the company, before the drug won approval."<sup id="cite_ref-medpage_52-1" class="reference"><a href="#cite_note-medpage-52">[52]</a></sup></p><p>On 15 April 2015 in Cambridge, MA, Joan Finnegan Brooks of the Cystic Fibrosis Foundation, spoke about the role of Vertex and venture philanthropy to a panel of biotech leaders hosted by <a href="/wiki/Life_Sciences_Foundation" title="Life Sciences Foundation">Life Sciences Foundation</a> on the topic of patient advocacy in the biotech industry.<sup id="cite_ref-biotechhistory_2015_54-0" class="reference"><a href="#cite_note-biotechhistory_2015-54">[54]</a></sup> While Brooks, who has Cystic Fibrosis, expressed gratitude for Vertex' development of Kalydeco, she observed that "More than 25% of people are saying (in a surveys conducted by the CFF) that they are skipping medications or delaying medications or skipping doctor appointments because of cost of care issues." She added that "one of the things that the Foundation has done," is to "develop resources that can help patients bridge that gap through patient access programs, and so forth."<sup id="cite_ref-55" class="reference"><a href="#cite_note-55">[55]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(6)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=11" title="Edit section: See also" data-section="11" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-6 collapsible-block" id="mf-section-6">
<style data-mw-deduplicate="TemplateStyles:r936637989">.mw-parser-output .portal{border:solid #aaa 1px;padding:0}.mw-parser-output .portal.tleft{margin:0.5em 1em 0.5em 0}.mw-parser-output .portal.tright{margin:0.5em 0 0.5em 1em}.mw-parser-output .portal>ul{display:table;box-sizing:border-box;padding:0.1em;max-width:175px;background:#f9f9f9;font-size:85%;line-height:110%;font-style:italic;font-weight:bold}.mw-parser-output .portal>ul>li{display:table-row}.mw-parser-output .portal>ul>li>span:first-child{display:table-cell;padding:0.2em;vertical-align:middle;text-align:center}.mw-parser-output .portal>ul>li>span:last-child{display:table-cell;padding:0.2em 0.2em 0.2em 0.3em;vertical-align:middle}</style><div role="navigation" aria-label="Portals" class="noprint portal plainlist tright">
<ul><li><span><noscript><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/2a/Industry5.svg/28px-Industry5.svg.png" decoding="async" width="28" height="28" class="noviewer" data-file-width="512" data-file-height="512"></noscript><span class="lazy-image-placeholder" style="width: 28px;height: 28px;" data-src="//upload.wikimedia.org/wikipedia/commons/thumb/2/2a/Industry5.svg/28px-Industry5.svg.png" data-alt="" data-width="28" data-height="28" data-srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/2a/Industry5.svg/42px-Industry5.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/2a/Industry5.svg/56px-Industry5.svg.png 2x" data-class="noviewer"> </span></span><span><a href="/wiki/Portal:Companies" title="Portal:Companies">Companies portal</a></span></li></ul></div>
<ul><li><a href="/wiki/Cystic_Fibrosis_Foundation" title="Cystic Fibrosis Foundation">Cystic Fibrosis Foundation</a></li>
<li><a href="/wiki/Telaprevir" title="Telaprevir">Telaprevir</a></li></ul></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(7)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="References">References</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=12" title="Edit section: References" data-section="12" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-7 collapsible-block" id="mf-section-7">
<div class="reflist" style="list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="references"><li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.hoovers.com/company/Vertex_Pharmaceuticals_Incorporated/rhytri-1.html">"Vertex Pharmaceuticals Incorporated"</a>. <a href="/wiki/Hoover%27s" class="mw-redirect" title="Hoover's">Hoover's</a><span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vertex+Pharmaceuticals+Incorporated&amp;rft.pub=Hoover%27s&amp;rft_id=http%3A%2F%2Fwww.hoovers.com%2Fcompany%2FVertex_Pharmaceuticals_Incorporated%2Frhytri-1.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r935243608">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-Globe-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-Globe_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Globe_2-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Weisman, Robert (24 April 2011). <a rel="nofollow" class="external text" href="http://www.boston.com/business/healthcare/articles/2011/04/24/can_vertex_transform_itself_into_a_money_making_enterprise/">"Rearranging the Corporate DNA"</a>. <i><a href="/wiki/The_Boston_Globe" title="The Boston Globe">Boston Sunday Globe</a></i>. p. G1<span class="reference-accessdate">. Retrieved <span class="nowrap">25 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Boston+Sunday+Globe&amp;rft.atitle=Rearranging+the+Corporate+DNA&amp;rft.pages=G1&amp;rft.date=2011-04-24&amp;rft.aulast=Weisman&amp;rft.aufirst=Robert&amp;rft_id=http%3A%2F%2Fwww.boston.com%2Fbusiness%2Fhealthcare%2Farticles%2F2011%2F04%2F24%2Fcan_vertex_transform_itself_into_a_money_making_enterprise%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-molecule-book-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-molecule-book_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-molecule-book_3-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation book"><a href="/wiki/Barry_Werth" title="Barry Werth">Werth, Barry</a> (1994). <a href="/wiki/The_Billion-Dollar_Molecule" title="The Billion-Dollar Molecule"><i>The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug</i></a>. New York: Simon &amp; Schuster. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a> <a href="/wiki/Special:BookSources/0671510576" title="Special:BookSources/0671510576"><bdi>0671510576</bdi></a>. <a href="/wiki/OCLC" title="OCLC">OCLC</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/oclc/32047662">32047662</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Billion-Dollar+Molecule%3A+One+Company%27s+Quest+for+the+Perfect+Drug&amp;rft.place=New+York&amp;rft.pub=Simon+%26+Schuster&amp;rft.date=1994&amp;rft_id=info%3Aoclcnum%2F32047662&amp;rft.isbn=0671510576&amp;rft.aulast=Werth&amp;rft.aufirst=Barry&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"> <i><a rel="nofollow" class="external text" href="https://books.google.com/books?id=Pw4_sKSwizYC">The Billion-Dollar Molecule</a></i> at <a href="/wiki/Google_Books" title="Google Books">Google Books</a>.</span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><cite class="citation book"><a href="/wiki/Barry_Werth" title="Barry Werth">Werth, Barry</a> (2014). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=k1y9AgAAQBAJ"><i>The Antidote: Inside the World of New Pharma</i></a>. New York: Simon &amp; Schuster. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a> <a href="/wiki/Special:BookSources/9781451655667" title="Special:BookSources/9781451655667"><bdi>9781451655667</bdi></a>. <a href="/wiki/OCLC" title="OCLC">OCLC</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/oclc/859375019">859375019</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Antidote%3A+Inside+the+World+of+New+Pharma&amp;rft.place=New+York&amp;rft.pub=Simon+%26+Schuster&amp;rft.date=2014&amp;rft_id=info%3Aoclcnum%2F859375019&amp;rft.isbn=9781451655667&amp;rft.aulast=Werth&amp;rft.aufirst=Barry&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3Dk1y9AgAAQBAJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-reports-fourth-quarter-and-full-year-2004">"Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance"</a>. <i>Vertex Pharmaceuticals</i><span class="reference-accessdate">. Retrieved <span class="nowrap">30 May</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Vertex+Pharmaceuticals&amp;rft.atitle=Vertex+Pharmaceuticals+Reports+Fourth+Quarter+and+Full+Year+2004+Financial+Results+and+Full+Year+2005+Guidance&amp;rft_id=https%3A%2F%2Finvestors.vrtx.com%2Fnews-releases%2Fnews-release-details%2Fvertex-pharmaceuticals-reports-fourth-quarter-and-full-year-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.forbes.com/companies/vertex-pharmaceuticals/">"Vertex Pharmaceuticals on the Forbes Global 2000 List"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">30 May</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=Vertex+Pharmaceuticals+on+the+Forbes+Global+2000+List&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fcompanies%2Fvertex-pharmaceuticals%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Boston_Globe_2015-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-Boston_Globe_2015_7-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFRobert_Weisman2015" class="citation">Robert Weisman (17 April 2015), <a rel="nofollow" class="external text" href="https://www.bostonglobe.com/business/2015/04/17/vertex-chief-compensation-totaled-million-last-year-including-retention-bonus/ihEVTF0DOwFJgMyJFGDZZN/story.html#"><i>Vertex chief's compensation totaled $36.6 million last year: Total included a retention bonus</i></a>, Boston Globe<span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Vertex+chief%27s+compensation+totaled+%2436.6+million+last+year%3A+Total+included+a+retention+bonus&amp;rft.pub=Boston+Globe&amp;rft.date=2015-04-17&amp;rft.au=Robert+Weisman&amp;rft_id=https%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2015%2F04%2F17%2Fvertex-chief-compensation-totaled-million-last-year-including-retention-bonus%2FihEVTF0DOwFJgMyJFGDZZN%2Fstory.html%23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation web">Staff, Robert Weisman Globe; February 4; 2014; Comments, 12:00 a m Email to a Friend Share on Facebook Share on TwitterPrint this Article View. <a rel="nofollow" class="external text" href="https://www.bostonglobe.com/business/2014/02/04/vertex-brings-together-farflung-employees-new-headquarters-south-boston-waterfront/AzeT8OtdoBZp0DCcQgr6hL/story.html">"New complex unites Vertex employees – The Boston Globe"</a>. <i>BostonGlobe.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">30 May</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BostonGlobe.com&amp;rft.atitle=New+complex+unites+Vertex+employees+%E2%80%93+The+Boston+Globe&amp;rft.aulast=Staff&amp;rft.aufirst=Robert+Weisman+Globe&amp;rft.au=February+4&amp;rft.au=2014&amp;rft.au=Comments%2C+12%3A00+a+m+Email+to+a+Friend+Share+on+Facebook+Share+on+TwitterPrint+this+Article+View&amp;rft_id=https%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2014%2F02%2F04%2Fvertex-brings-together-farflung-employees-new-headquarters-south-boston-waterfront%2FAzeT8OtdoBZp0DCcQgr6hL%2Fstory.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><cite class="citation news">Owens, Jeremy C. (23 January 2019). <a rel="nofollow" class="external text" href="https://www.marketwatch.com/story/vertex-terminates-coo-for-personal-behavior-2019-01-23">"Vertex terminates COO for 'personal behavior<span class="cs1-kern-right">'</span>"</a>. <i><a href="/wiki/MarketWatch" title="MarketWatch">MarketWatch</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">25 January</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=MarketWatch&amp;rft.atitle=Vertex+terminates+COO+for+%27personal+behavior%27&amp;rft.date=2019-01-23&amp;rft.aulast=Owens&amp;rft.aufirst=Jeremy+C.&amp;rft_id=https%3A%2F%2Fwww.marketwatch.com%2Fstory%2Fvertex-terminates-coo-for-personal-behavior-2019-01-23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://www.biospace.com/article/releases/vertex-expands-into-new-disease-areas-and-enhances-gene-editing-capabilities-through-expanded-collaboration-with-crispr-therapeutics-and-acquisition-of-exonics-therapeutics/?s=79">https://www.biospace.com/article/releases/vertex-expands-into-new-disease-areas-and-enhances-gene-editing-capabilities-through-expanded-collaboration-with-crispr-therapeutics-and-acquisition-of-exonics-therapeutics/?s=79</a></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://www.biospace.com/article/vertex-dives-into-dmd-with-exonics-acquisition-and-expansion-of-partnership-with-crispr-therapeutics/?s=79">https://www.biospace.com/article/vertex-dives-into-dmd-with-exonics-acquisition-and-expansion-of-partnership-with-crispr-therapeutics/?s=79</a></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://uk.reuters.com/article/us-semma-therapeutics-m-a-vertex-pharms/vertex-to-buy-cell-therapy-developer-semma-for-950-million-idUKKCN1VO1DZ">https://uk.reuters.com/article/us-semma-therapeutics-m-a-vertex-pharms/vertex-to-buy-cell-therapy-developer-semma-for-950-million-idUKKCN1VO1DZ</a></span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><cite class="citation web">Time Staff. <a rel="nofollow" class="external text" href="https://time.com/5710295/top-health-innovations/">"12 Innovations That Will Change Health Care and Medicine in the 2020s"</a>. <i>Time</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 October</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Time&amp;rft.atitle=12+Innovations+That+Will+Change+Health+Care+and+Medicine+in+the+2020s&amp;rft.au=Time+Staff&amp;rft_id=https%3A%2F%2Ftime.com%2F5710295%2Ftop-health-innovations%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-:1-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_14-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">DeAngelis, Allison (2 April 2020). <a rel="nofollow" class="external text" href="https://www.bizjournals.com/boston/news/2020/04/02/vertex-enters-new-era-of-leadership-drug.html">"VERTEX 3.0: One of the area's largest biotechs enters new era of leadership, drug development"</a>. <i>www.bizjournals.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">6 April</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bizjournals.com&amp;rft.atitle=VERTEX+3.0%3A+One+of+the+area%27s+largest+biotechs+enters+new+era+of+leadership%2C+drug+development&amp;rft.date=2020-04-02&amp;rft.aulast=DeAngelis&amp;rft.aufirst=Allison&amp;rft_id=https%3A%2F%2Fwww.bizjournals.com%2Fboston%2Fnews%2F2020%2F04%2F02%2Fvertex-enters-new-era-of-leadership-drug.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://endpts.com/vertexs-cmo-reshma-kewalramani-takes-ceo-post-as-longtime-vet-jeff-leiden-moves-to-new-role/">"Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role"</a>. <i>Endpoints News</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Endpoints+News&amp;rft.atitle=Vertex%27s+Reshma+Kewalramani+takes+CEO+post+as+longtime+vet+Jeff+Leiden+moves+to+new+role&amp;rft_id=https%3A%2F%2Fendpts.com%2Fvertexs-cmo-reshma-kewalramani-takes-ceo-post-as-longtime-vet-jeff-leiden-moves-to-new-role%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.statnews.com/2019/07/25/vertex-pharmaceuticals-jeffrey-leiden-to-step-aside-as-ceo/">"Vertex Pharmaceuticals' Jeffrey Leiden to step aside as CEO"</a>. <i>STAT</i>. 25 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=STAT&amp;rft.atitle=Vertex+Pharmaceuticals%27+Jeffrey+Leiden+to+step+aside+as+CEO&amp;rft.date=2019-07-25&amp;rft_id=https%3A%2F%2Fwww.statnews.com%2F2019%2F07%2F25%2Fvertex-pharmaceuticals-jeffrey-leiden-to-step-aside-as-ceo%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-FDA_2011-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA_2011_17-0">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm">"FDA approves Kalydeco to treat rare form of cystic fibrosis"</a> (Press release). <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>. 31 January 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+Kalydeco+to+treat+rare+form+of+cystic+fibrosis&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2011-01-31&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm289633.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.kalydeco.com/">"KALYDECO™ (ivacaftor) tablets"</a>. Vertex Pharmaceuticals<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=KALYDECO%E2%84%A2+%28ivacaftor%29+tablets&amp;rft.pub=Vertex+Pharmaceuticals&amp;rft_id=http%3A%2F%2Fwww.kalydeco.com%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><cite class="citation news">Walker, Joseph; Rockoff, Jonathan D. (19 November 2014). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/cystic-fibrosis-foundation-sells-drugs-rights-for-3-3-billion-1416414300">"Cystic Fibrosis Foundation Sells Drug's Rights for $3.3 Billion"</a>. <i>Wall Street Journal</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0099-9660">0099-9660</a><span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Cystic+Fibrosis+Foundation+Sells+Drug%27s+Rights+for+%243.3+Billion&amp;rft.date=2014-11-19&amp;rft.issn=0099-9660&amp;rft.aulast=Walker&amp;rft.aufirst=Joseph&amp;rft.au=Rockoff%2C+Jonathan+D.&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fcystic-fibrosis-foundation-sells-drugs-rights-for-3-3-billion-1416414300&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><cite class="citation web">Herper, Matthew. <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2017/08/08/vertex-pharmaceuticals-and-the-price-of-inspiration/">"For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=For+Vertex+Pharmaceuticals%2C+Can+One+Billion-Dollar+Breakthrough+Beget+Another%3F&amp;rft.aulast=Herper&amp;rft.aufirst=Matthew&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2017%2F08%2F08%2Fvertex-pharmaceuticals-and-the-price-of-inspiration%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.vrtx.com/current-projects/drug-candidates/VX-809.html">"VX-809 (Cystic Fibrosis)"</a>. Vertex Pharmaceuticals. 7 September 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=VX-809+%28Cystic+Fibrosis%29&amp;rft.pub=Vertex+Pharmaceuticals&amp;rft.date=2011-09-07&amp;rft_id=http%3A%2F%2Fwww.vrtx.com%2Fcurrent-projects%2Fdrug-candidates%2FVX-809.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2012-01-31/fda-approves-vertex-s-kalydeco-for-cystic-fibrosis">"Vertex Wins Approval for Kalydeco to Treat Cystic Fibrosis"</a>. 31 January 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vertex+Wins+Approval+for+Kalydeco+to+Treat+Cystic+Fibrosis&amp;rft.date=2012-01-31&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2012-01-31%2Ffda-approves-vertex-s-kalydeco-for-cystic-fibrosis&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://xconomy.com/boston/2011/10/19/vertex-seeks-fda-green-light-for-cystic-fibrosis-drug-second-potential-hit-of-big-year/">"Xconomy: Vertex Seeks FDA Green Light for Cystic Fibrosis Drug, Second Potential Hit of Big Year"</a>. <i>Xconomy</i>. 19 October 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Xconomy&amp;rft.atitle=Xconomy%3A+Vertex+Seeks+FDA+Green+Light+for+Cystic+Fibrosis+Drug%2C+Second+Potential+Hit+of+Big+Year&amp;rft.date=2011-10-19&amp;rft_id=https%3A%2F%2Fxconomy.com%2Fboston%2F2011%2F10%2F19%2Fvertex-seeks-fda-green-light-for-cystic-fibrosis-drug-second-potential-hit-of-big-year%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-BMJ-2014-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-BMJ-2014_24-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Deborah Cohen; James Raftery (12 February 2014). <a rel="nofollow" class="external text" href="http://www.bmj.com/content/348/bmj.g1445">"Orphan Drugs: Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding"</a>. <i><a href="/wiki/BMJ" class="mw-redirect" title="BMJ">BMJ</a></i>. <b>348</b>: g1445. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1136%2Fbmj.g1445">10.1136/bmj.g1445</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a> <a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24523379">24523379</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ&amp;rft.atitle=Orphan+Drugs%3A+Paying+twice%3A+questions+over+high+cost+of+cystic+fibrosis+drug+developed+with+charitable+funding&amp;rft.volume=348&amp;rft.pages=g1445&amp;rft.date=2014-02-12&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.g1445&amp;rft_id=info%3Apmid%2F24523379&amp;rft.au=Deborah+Cohen&amp;rft.au=James+Raftery&amp;rft_id=http%3A%2F%2Fwww.bmj.com%2Fcontent%2F348%2Fbmj.g1445&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=880537">http://investors.vrtx.com/releasedetail.cfm?ReleaseID=880537</a></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation web">Commissioner, Office of the. <a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm">"Press Announcements – FDA approves new treatment for cystic fibrosis"</a>. <i>www.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">16 January</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Press+Announcements+%E2%80%93+FDA+approves+new+treatment+for+cystic+fibrosis&amp;rft.aulast=Commissioner&amp;rft.aufirst=Office+of+the&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm453565.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2017/03/29/is-vertexs-new-cf-drug-incremental-unprecedented-expensive-maybe-all-three/#6dd71f7a28b2">"Is Vertex's New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three"</a>. <i>Forbes</i>. 29 March 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=Is+Vertex%27s+New+CF+Drug+Unprecedented%3F+Incremental%3F+Expensive%3F+Maybe+All+Three&amp;rft.date=2017-03-29&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2017%2F03%2F29%2Fis-vertexs-new-cf-drug-incremental-unprecedented-expensive-maybe-all-three%2F%236dd71f7a28b2&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-cystic-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-cystic_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cystic_28-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://cysticfibrosisnewstoday.com/2018/09/17/vertex-and-treating-cf-high-hopes-for-triple-combos-and-gene-therapy-possibilities-part-three-interview-series/">"Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities"</a>. Cystic Fibrosis News Today. 17 September 2018.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vertex+and+Treating+CF%3A+High+Hopes+for+Triple+Combinations+and+Gene+Therapy+Possibilities&amp;rft.pub=Cystic+Fibrosis+News+Today&amp;rft.date=2018-09-17&amp;rft_id=https%3A%2F%2Fcysticfibrosisnewstoday.com%2F2018%2F09%2F17%2Fvertex-and-treating-cf-high-hopes-for-triple-combos-and-gene-therapy-possibilities-part-three-interview-series%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2017/07/18/new-vertex-drugs-show-dramatic-benefit-in-cystic-fibrosis/#5b9468912f95">"<span class="cs1-kern-left">'</span>Just What We Dreamed.' New Vertex Drugs Show Dramatic Benefit Against Cystic Fibrosis"</a>. <i><a href="/wiki/Forbes" title="Forbes">Forbes</a></i>. 18 July 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=%27Just+What+We+Dreamed.%27+New+Vertex+Drugs+Show+Dramatic+Benefit+Against+Cystic+Fibrosis&amp;rft.date=2017-07-18&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2017%2F07%2F18%2Fnew-vertex-drugs-show-dramatic-benefit-in-cystic-fibrosis%2F%235b9468912f95&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis">"FDA approves new breakthrough therapy for cystic fibrosis"</a>. <a href="/wiki/FDA" class="mw-redirect" title="FDA">FDA</a>. 21 October 2019.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+new+breakthrough+therapy+for+cystic+fibrosis&amp;rft.pub=FDA&amp;rft.date=2019-10-21&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-breakthrough-therapy-cystic-fibrosis&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-:0-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_31-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">Parsons, Lucy (24 October 2019). <a rel="nofollow" class="external text" href="https://www.pmlive.com/pharma_news/vertex,_nhs_england_and_nice_finally_reach_agreement_for_orkambi_1314406">"Vertex, NHS England and NICE finally reach agreement for Orkambi"</a>. <i>PMLive</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 October</span> 2019</span>. <q>The triple therapy, which has just received approval from the FDA in the US, is thought to be effective in up to 90% of CF patients.</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=PMLive&amp;rft.atitle=Vertex%2C+NHS+England+and+NICE+finally+reach+agreement+for+Orkambi&amp;rft.date=2019-10-24&amp;rft.aulast=Parsons&amp;rft.aufirst=Lucy&amp;rft_id=https%3A%2F%2Fwww.pmlive.com%2Fpharma_news%2Fvertex%2C_nhs_england_and_nice_finally_reach_agreement_for_orkambi_1314406&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://xconomy.com/boston/2015/10/26/vertex-crispr-tx-team-up-on-gene-editing-drugs-in-105m-pact/">"Vertex, CRISPR Tx Team up on Gene Editing Drugs in $105M Pact"</a>. Exome. 26 October 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vertex%2C+CRISPR+Tx+Team+up+on+Gene+Editing+Drugs+in+%24105M+Pact&amp;rft.pub=Exome&amp;rft.date=2015-10-26&amp;rft_id=https%3A%2F%2Fxconomy.com%2Fboston%2F2015%2F10%2F26%2Fvertex-crispr-tx-team-up-on-gene-editing-drugs-in-105m-pact%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation journal"><a rel="nofollow" class="external text" href="http://www.genengnews.com/gen-news-highlights/vertex-moderna-launch-cystic-fibrosis-collaboration/81252914/">"Vertex, Moderna Launch Cystic Fibrosis Collaboration"</a>. News: Discovery &amp; Development. <i><a href="/wiki/Gen._Eng._Biotechnol._News" class="mw-redirect" title="Gen. Eng. Biotechnol. News">Genetic Engineering &amp; Biotechnology News</a></i> (Paper). <b>36</b> (14): 17. August 2016.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Genetic+Engineering+%26+Biotechnology+News&amp;rft.atitle=Vertex%2C+Moderna+Launch+Cystic+Fibrosis+Collaboration&amp;rft.volume=36&amp;rft.issue=14&amp;rft.pages=17&amp;rft.date=2016-08&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fvertex-moderna-launch-cystic-fibrosis-collaboration%2F81252914%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><cite class="citation web">DeAngelis, Allison (3 January 2019). <a rel="nofollow" class="external text" href="https://www.bizjournals.com/boston/news/2019/01/03/vertex-teams-up-with-feng-zhang-startup-on-gene.html">"Vertex teams up with Feng Zhang startup on gene editing tech"</a>. <i>www.bizjournals.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bizjournals.com&amp;rft.atitle=Vertex+teams+up+with+Feng+Zhang+startup+on+gene+editing+tech&amp;rft.date=2019-01-03&amp;rft.aulast=DeAngelis&amp;rft.aufirst=Allison&amp;rft_id=https%3A%2F%2Fwww.bizjournals.com%2Fboston%2Fnews%2F2019%2F01%2F03%2Fvertex-teams-up-with-feng-zhang-startup-on-gene.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation web">Silverman, Ed (12 August 2014). <a rel="nofollow" class="external text" href="https://blogs.wsj.com/pharmalot/2014/08/12/from-riches-to-rags-vertex-discontinues-incivek-as-sales-evaporate/">"From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate"</a>. <i>Pharmalot</i> (Blog). Dow Jones &amp; Company<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Pharmalot&amp;rft.atitle=From+Riches+to+Rags%3A+Vertex+Discontinues+Incivek+as+Sales+Evaporate&amp;rft.date=2014-08-12&amp;rft.aulast=Silverman&amp;rft.aufirst=Ed&amp;rft_id=https%3A%2F%2Fblogs.wsj.com%2Fpharmalot%2F2014%2F08%2F12%2Ffrom-riches-to-rags-vertex-discontinues-incivek-as-sales-evaporate%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="https://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm">"Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV)"</a> (Press release). <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>. 24 May 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">25 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Approval+of+Incivek+%28telaprevir%29%2C+a+direct+acting+antiviral+drug+%28DAA%29+to+treat+hepatitis+C+%28HCV%29&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2011-05-24&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FForConsumers%2FByAudience%2FForPatientAdvocates%2Fucm256328.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation web">Bloomberg (26 May 2015). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2015-05-26/vertex-ceo-s-45-8-million-pay-last-year-excessive-iss-says">"Vertex CEO's $45.8 Million Pay Last Year Excessive, ISS Says"</a>. <i>www.bloomberg.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bloomberg.com&amp;rft.atitle=Vertex+CEO%27s+%2445.8+Million+Pay+Last+Year+Excessive%2C+ISS+Says&amp;rft.date=2015-05-26&amp;rft.au=Bloomberg&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2015-05-26%2Fvertex-ceo-s-45-8-million-pay-last-year-excessive-iss-says&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite class="citation web">Reporter, Robert Weisman-. <a rel="nofollow" class="external text" href="https://www.bostonglobe.com/business/2017/04/17/vertex-ceo-pay-falls-second-straight-decline/hjavbxdKfJbQwCZODVNTcJ/story.html">"Vertex CEO's pay falls 38% to $17.4m in second straight decline – The Boston Globe"</a>. <i>BostonGlobe.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BostonGlobe.com&amp;rft.atitle=Vertex+CEO%27s+pay+falls+38%25+to+%2417.4m+in+second+straight+decline+%E2%80%93+The+Boston+Globe&amp;rft.aulast=Reporter&amp;rft.aufirst=Robert+Weisman-&amp;rft_id=https%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F04%2F17%2Fvertex-ceo-pay-falls-second-straight-decline%2FhjavbxdKfJbQwCZODVNTcJ%2Fstory.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation news">Thomas, Katie (24 June 2018). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2018/06/24/health/drug-prices-orkambi-new-york.html">"A Drug Costs $272,000 a Year. Not So Fast, Says New York State"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=A+Drug+Costs+%24272%2C000+a+Year.+Not+So+Fast%2C+Says+New+York+State.&amp;rft.date=2018-06-24&amp;rft.issn=0362-4331&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2018%2F06%2F24%2Fhealth%2Fdrug-prices-orkambi-new-york.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><cite class="citation web">24 Jul, Lisa Johnson · CBC News · Posted; July 25, 2018 7:50 PM PT | Last Updated; 2018. <a rel="nofollow" class="external text" href="https://www.cbc.ca/news/canada/british-columbia/orkambi-cystic-fibrosis-lawsuit-1.4759935">"Cystic fibrosis patients sue health ministers for coverage of expensive drug for rare disease | CBC News"</a>. <i>CBC</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CBC&amp;rft.atitle=Cystic+fibrosis+patients+sue+health+ministers+for+coverage+of+expensive+drug+for+rare+disease+%7C+CBC+News&amp;rft.aulast=24+Jul&amp;rft.aufirst=Lisa+Johnson+%C2%B7+CBC+News+%C2%B7+Posted&amp;rft.au=July+25%2C+2018+7%3A50+PM+PT+%7C+Last+Updated&amp;rft.au=2018&amp;rft_id=https%3A%2F%2Fwww.cbc.ca%2Fnews%2Fcanada%2Fbritish-columbia%2Forkambi-cystic-fibrosis-lawsuit-1.4759935&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation news">editor, Sarah Boseley Health (3 February 2019). <a rel="nofollow" class="external text" href="https://www.theguardian.com/society/2019/feb/03/cystic-fibrosis-patients-shorter-lives-orkambi-expense-nhs">"Cystic fibrosis: the patients facing shorter lives due to drug's expense"</a>. <i>The Guardian</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0261-3077">0261-3077</a><span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Guardian&amp;rft.atitle=Cystic+fibrosis%3A+the+patients+facing+shorter+lives+due+to+drug%27s+expense&amp;rft.date=2019-02-03&amp;rft.issn=0261-3077&amp;rft.aulast=editor&amp;rft.aufirst=Sarah+Boseley+Health&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fsociety%2F2019%2Ffeb%2F03%2Fcystic-fibrosis-patients-shorter-lives-orkambi-expense-nhs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><span class="cs1-maint citation-comment">CS1 maint: extra text: authors list (<a href="/wiki/Category:CS1_maint:_extra_text:_authors_list" title="Category:CS1 maint: extra text: authors list">link</a>)</span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.cfsupportgroup.org/letter-to-jeffrey-leiden">"CF Support Group | Letter to Dr Jeffrey Leiden"</a>. <i>CF Support Group</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CF+Support+Group&amp;rft.atitle=CF+Support+Group+%7C+Letter+to+Dr+Jeffrey+Leiden&amp;rft_id=https%3A%2F%2Fwww.cfsupportgroup.org%2Fletter-to-jeffrey-leiden&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.patientsforaffordabledrugs.org/2018/05/17/cystic-fibrosis-community/">"The problem is the price: 5 reasons the cystic fibrosis community and its allies must band together to speak out about our drug prices – right now"</a>. <i>Patients For Affordable Drugs</i>. 17 May 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Patients+For+Affordable+Drugs&amp;rft.atitle=The+problem+is+the+price%3A+5+reasons+the+cystic+fibrosis+community+and+its+allies+must+band+together+to+speak+out+about+our+drug+prices+%E2%80%93+right+now.&amp;rft.date=2018-05-17&amp;rft_id=https%3A%2F%2Fwww.patientsforaffordabledrugs.org%2F2018%2F05%2F17%2Fcystic-fibrosis-community%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Boseley_2019-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-Boseley_2019_44-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Boseley, Sarah (27 March 2019). <a rel="nofollow" class="external text" href="https://www.theguardian.com/society/2019/mar/27/600-years-supply-of-cystic-fibrosis-drug-destroyed-in-price-row">"600 years' supply of cystic fibrosis drug destroyed in price row"</a>. <i>the Guardian</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 March</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=the+Guardian&amp;rft.atitle=600+years%27+supply+of+cystic+fibrosis+drug+destroyed+in+price+row&amp;rft.date=2019-03-27&amp;rft.aulast=Boseley&amp;rft.aufirst=Sarah&amp;rft_id=http%3A%2F%2Fwww.theguardian.com%2Fsociety%2F2019%2Fmar%2F27%2F600-years-supply-of-cystic-fibrosis-drug-destroyed-in-price-row&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.biospace.com/article/nearly-8-000-packets-of-orkambi-destroyed-as-the-u-k-and-vertex-hash-out-pricing-concerns/">"Nearly 8,000 Packets of Orkambi Destroyed as the U.K. and Vertex Hash out Pricing Concerns"</a>. <i>BioSpace</i><span class="reference-accessdate">. Retrieved <span class="nowrap">19 June</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BioSpace&amp;rft.atitle=Nearly+8%2C000+Packets+of+Orkambi+Destroyed+as+the+U.K.+and+Vertex+Hash+out+Pricing+Concerns&amp;rft_id=https%3A%2F%2Fwww.biospace.com%2Farticle%2Fnearly-8-000-packets-of-orkambi-destroyed-as-the-u-k-and-vertex-hash-out-pricing-concerns%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><cite class="citation web">Silverman, Ed (24 October 2019). <a rel="nofollow" class="external text" href="https://www.statnews.com/pharmalot/2019/10/24/vertex-uk-cystic-fibrosis-drug-prices-deal/">"Vertex and the U.K. reach a deal for cystic fibrosis medicines"</a>. <i>STAT</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 October</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=STAT&amp;rft.atitle=Vertex+and+the+U.K.+reach+a+deal+for+cystic+fibrosis+medicines&amp;rft.date=2019-10-24&amp;rft.aulast=Silverman&amp;rft.aufirst=Ed&amp;rft_id=https%3A%2F%2Fwww.statnews.com%2Fpharmalot%2F2019%2F10%2F24%2Fvertex-uk-cystic-fibrosis-drug-prices-deal%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.hsj.co.uk/commissioning/nhs-england-finally-strikes-deal-for-high-value-drug/7026224.article">"NHS England finally strikes deal for high value drug"</a>. Health Service Journal. 24 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">3 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=NHS+England+finally+strikes+deal+for+high+value+drug&amp;rft.date=2019-10-24&amp;rft_id=https%3A%2F%2Fwww.hsj.co.uk%2Fcommissioning%2Fnhs-england-finally-strikes-deal-for-high-value-drug%2F7026224.article&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYT_2014-48"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYT_2014_48-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT_2014_48-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFAndrew_Pollack2014" class="citation">Andrew Pollack (19 November 2014), <a rel="nofollow" class="external text" href="https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html?_r=0">"Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern"</a>, <i>New York Times</i><span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Deal+by+Cystic+Fibrosis+Foundation+Raises+Cash+and+Some+Concern&amp;rft.date=2014-11-19&amp;rft.au=Andrew+Pollack&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2014%2F11%2F19%2Fbusiness%2Ffor-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html%3F_r%3D0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite id="CITEREFJoseph_WalkerJonathan_D._Rockoff2014" class="citation">Joseph Walker; Jonathan D. Rockoff (19 November 2014), <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/cystic-fibrosis-foundation-sells-drugs-rights-for-3-3-billion-1416414300"><i>Cystic Fibrosis Foundation Sells Drug's Rights for $3.3 Billion: The Biggest Royalty Purchase Ever Reflects Group's Share of Kalydeco Sales</i></a>, Wall Street Journal<span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Cystic+Fibrosis+Foundation+Sells+Drug%27s+Rights+for+%243.3+Billion%3A+The+Biggest+Royalty+Purchase+Ever+Reflects+Group%27s+Share+of+Kalydeco+Sales&amp;rft.pub=Wall+Street+Journal&amp;rft.date=2014-11-19&amp;rft.au=Joseph+Walker&amp;rft.au=Jonathan+D.+Rockoff&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fcystic-fibrosis-foundation-sells-drugs-rights-for-3-3-billion-1416414300&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><cite class="citation news">Pollack, Andrew (19 November 2014). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html">"Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">9 July</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Deal+by+Cystic+Fibrosis+Foundation+Raises+Cash+and+Some+Concern&amp;rft.date=2014-11-19&amp;rft.issn=0362-4331&amp;rft.aulast=Pollack&amp;rft.aufirst=Andrew&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2014%2F11%2F19%2Fbusiness%2Ffor-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Dennis_WP_2015-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-Dennis_WP_2015_51-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFBrady_Dennis2015" class="citation">Brady Dennis (2 July 2015), <a rel="nofollow" class="external text" href="https://www.washingtonpost.com/national/health-science/in-hunt-for-new-treatments-nonprofits-are-acting-like-venture-capitalists/2015/07/02/c6094578-19b8-11e5-93b7-5eddc056ad8a_story.html">"Are risks worth the rewards when nonprofits act like venture capitalists?"</a>, <i>Washington Post</i><span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Washington+Post&amp;rft.atitle=Are+risks+worth+the+rewards+when+nonprofits+act+like+venture+capitalists%3F&amp;rft.date=2015-07-02&amp;rft.au=Brady+Dennis&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Fnational%2Fhealth-science%2Fin-hunt-for-new-treatments-nonprofits-are-acting-like-venture-capitalists%2F2015%2F07%2F02%2Fc6094578-19b8-11e5-93b7-5eddc056ad8a_story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-medpage-52"><span class="mw-cite-backlink">^ <a href="#cite_ref-medpage_52-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-medpage_52-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web">John Fauber (19 May 2013). <a rel="nofollow" class="external text" href="http://www.medpagetoday.com/Pulmonology/CysticFibrosis/39217">"Cystic Fibrosis: Charity and Industry Partner for Profit"</a>. MedPage Today, Milwaukee Journal Sentinel<span class="reference-accessdate">. Retrieved <span class="nowrap">19 July</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Cystic+Fibrosis%3A+Charity+and+Industry+Partner+for+Profit&amp;rft.pub=MedPage+Today%2C+Milwaukee+Journal+Sentinel&amp;rft.date=2013-05-19&amp;rft.au=John+Fauber&amp;rft_id=http%3A%2F%2Fwww.medpagetoday.com%2FPulmonology%2FCysticFibrosis%2F39217&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Vertex_letter_2012-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-Vertex_letter_2012_53-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFDavid_M._OrensteinPaul_M._QuintonBrian_P._O'SullivanCarlos_E._Milla2012" class="citation">David M. Orenstein; Paul M. Quinton; Brian P. O'Sullivan; Carlos E. Milla; Mark Pian;  et al. (9 July 2012), <a rel="nofollow" class="external text" href="http://www.medpagetoday.com/upload/2013/5/17/CFletter.pdf"><i>Letter to Jeff Leiden, CEO of Vertex Pharmaceuticals</i></a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Letter+to+Jeff+Leiden%2C+CEO+of+Vertex+Pharmaceuticals&amp;rft.date=2012-07-09&amp;rft.au=David+M.+Orenstein&amp;rft.au=Paul+M.+Quinton&amp;rft.au=Brian+P.+O%27Sullivan&amp;rft.au=Carlos+E.+Milla&amp;rft.au=Mark+Pian&amp;rft_id=http%3A%2F%2Fwww.medpagetoday.com%2Fupload%2F2013%2F5%2F17%2FCFletter.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-biotechhistory_2015-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-biotechhistory_2015_54-0">^</a></b></span> <span class="reference-text"><cite class="citation"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20160307131211/https://www.biotechhistory.org/event/voices-carry/">"Voices Carry: How History Informs Patient Advocacy in the Biotech Industry"</a>, <i>Life Sciences Foundation</i>, Cambridge, Massachusetts, 15 April 2015, archived from <a rel="nofollow" class="external text" href="http://biotechhistory.org/event/voices-carry/">the original</a> on 7 March 2016<span class="reference-accessdate">, retrieved <span class="nowrap">19 July</span> 2015</span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Life+Sciences+Foundation&amp;rft.atitle=Voices+Carry%3A+How+History+Informs+Patient+Advocacy+in+the+Biotech+Industry&amp;rft.date=2015-04-15&amp;rft_id=http%3A%2F%2Fbiotechhistory.org%2Fevent%2Fvoices-carry%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.youtube.com/watch?v=-QfVxHOp67c">"Voices Carry: How History Informs Patient Advocacy in the Biotech Industry"</a>. <i>YouTube</i>. 14 May 2014. 1 hour 3 min – 1 hour 5 min<span class="reference-accessdate">. Retrieved <span class="nowrap">3 July</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=YouTube&amp;rft.atitle=Voices+Carry%3A+How+History+Informs+Patient+Advocacy+in+the+Biotech+Industry&amp;rft.pages=1+hour+3+min+-+1+hour+5+min&amp;rft.date=2014-05-14&amp;rft_id=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D-QfVxHOp67c&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
</ol></div></div>
<ul><li><cite class="citation book"><a rel="nofollow" class="external text" href="http://investors.vrtx.com/secfiling.cfm?filingID=1047469-04-7993"><i>Annual Report</i></a>. Vertex Pharmaceuticals. 15 March 2004<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Annual+Report&amp;rft.pub=Vertex+Pharmaceuticals&amp;rft.date=2004-03-15&amp;rft_id=http%3A%2F%2Finvestors.vrtx.com%2Fsecfiling.cfm%3FfilingID%3D1047469-04-7993&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></li>
<li><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=532555">"Vertex Completes New Drug Application for Telaprevir for Hepatitis C"</a> (Press release). Vertex Pharmaceuticals. 23 November 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Vertex+Completes+New+Drug+Application+for+Telaprevir+for+Hepatitis+C&amp;rft.pub=Vertex+Pharmaceuticals&amp;rft.date=2010-11-23&amp;rft_id=http%3A%2F%2Finvestors.vrtx.com%2Freleasedetail.cfm%3FReleaseID%3D532555&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AVertex+Pharmaceuticals" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></li></ul></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(8)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><a href="/w/index.php?title=Vertex_Pharmaceuticals&amp;action=edit&amp;section=13" title="Edit section: External links" data-section="13" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-8 collapsible-block" id="mf-section-8">
<ul><li>Business data for Vertex Pharmaceuticals: <div class="hlist hlist-separated inline"><ul><li><a rel="nofollow" class="external text" href="https://www.google.com/finance?q=VRTX">Google Finance</a></li><li><a rel="nofollow" class="external text" href="https://finance.yahoo.com/q?s=VRTX">Yahoo! Finance</a></li><li><a rel="nofollow" class="external text" href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=VRTX">SEC filings</a></li></ul></div></li></ul>





</section></div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1&amp;mobile=1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Vertex_Pharmaceuticals&amp;oldid=950745030">https://en.wikipedia.org/w/index.php?title=Vertex_Pharmaceuticals&amp;oldid=950745030</a>"</div>
</div>
			<div class="post-content" id="page-secondary-actions">
			
			</div>
		</main>
		<footer class="minerva-footer">
		<div class="last-modified-bar">
	<div class="post-content last-modified-bar__content">
		<span class="last-modified-bar__icon mw-ui-icon mw-ui-icon-mw-ui-icon-small mw-ui-icon-wikimedia-history-base20 "></span>
		<a class="last-modified-bar__text" href="/wiki/Special:History/Vertex_Pharmaceuticals"
				data-user-name="Sunline09"
				data-user-gender="unknown"
				data-timestamp="1586795287">
				<span>Last edited on 13 April 2020, at 16:28</span>
		</a>
		<span class="mw-ui-icon mw-ui-icon-small mw-ui-icon-mf-expand-gray mf-mw-ui-icon-rotate-anti-clockwise indicator"></span>
	</div>
</div>

		<div class="post-content footer-content">
			<div id='mw-data-after-content'>
	<div class="read-more-container"></div>
</div>

			<h2><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></h2>
			<div class="license">Content is available under <a class="external" rel="nofollow" href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a> unless otherwise noted.</div>
			<ul class="footer-places hlist hlist-separated">
				<li id="footer-places-terms-use"><a href="//m.wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a></li><li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy</a></li><li id="footer-places-desktop-toggle"><a id="mw-mf-display-toggle" href="//en.wikipedia.org/w/index.php?title=Vertex_Pharmaceuticals&amp;mobileaction=toggle_view_desktop">Desktop</a></li>
			</ul>
		</div>
		</footer>
	</div>
</div>
<div class="mw-notification-area" data-mw="interface"></div>
<!-- v:8.3.0 -->

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.640","walltime":"0.839","ppvisitednodes":{"value":3354,"limit":1000000},"postexpandincludesize":{"value":140575,"limit":2097152},"templateargumentsize":{"value":3846,"limit":2097152},"expansiondepth":{"value":13,"limit":40},"expensivefunctioncount":{"value":5,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":173300,"limit":5000000},"entityaccesscount":{"value":4,"limit":400},"timingprofile":["100.00%  742.126      1 -total"," 53.97%  400.489      1 Template:Reflist"," 25.05%  185.935     31 Template:Cite_web"," 20.51%  152.247      1 Template:Infobox_company"," 18.65%  138.434      1 Template:Infobox","  8.27%   61.357     10 Template:Wikidata","  7.51%   55.742      8 Template:Cite_news","  6.72%   49.901      1 Template:Br_separated_entries","  6.10%   45.237      3 Template:Cite_book","  5.88%   43.643      1 Template:Use_dmy_dates"]},"scribunto":{"limitreport-timeusage":{"value":"0.370","limit":"10.000"},"limitreport-memusage":{"value":8864185,"limit":52428800}},"cachereport":{"origin":"mw1401","timestamp":"20200416052544","ttl":2592000,"transientcontent":false}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Vertex Pharmaceuticals","url":"https:\/\/en.wikipedia.org\/wiki\/Vertex_Pharmaceuticals","sameAs":"http:\/\/www.wikidata.org\/entity\/Q2744099","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q2744099","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2005-05-20T04:43:24Z","dateModified":"2020-04-13T16:28:07Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/en\/d\/d9\/Vertex_logo.svg","headline":"American pharmaceutical company"}</script><script>(window.NORLQ=window.NORLQ||[]).push(function(){var ns,i,p,img;ns=document.getElementsByTagName('noscript');for(i=0;i<ns.length;i++){p=ns[i].nextSibling;if(p&&p.className&&p.className.indexOf('lazy-image-placeholder')>-1){img=document.createElement('img');img.setAttribute('src',p.getAttribute('data-src'));img.setAttribute('width',p.getAttribute('data-width'));img.setAttribute('height',p.getAttribute('data-height'));img.setAttribute('alt',p.getAttribute('data-alt'));p.parentNode.replaceChild(img,p);}}});</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":151,"wgHostname":"mw1261"});});</script>		</body>
		</html>
		